Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors

The novel spiro[isobenzofuran-1,2′-pyran] structure is proved to be an effective scaffold for diversification of SGLT2 inhibitors and a number of compounds with single digit nanomolar potency and high selectivity have been synthesized.